Crystalline Ingenol Mebutate

Patent No. EP2558435 (titled "Crystalline Ingenol Mebutate") was filed by LEO Pharma on Apr 18, 2011. The application was issued on Jun 7, 2017.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKMar 7, 2018FRKELLY
TEVA PHARMACEUTICALSMar 7, 2018D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2558435

LEO PHARMA
Application Number
EP11731076A
Filing Date
Apr 18, 2011
Status
Revoked
Jun 14, 2019
Publication Date
Jun 7, 2017